

## CERTIFICATE OF ANALYSIS


### ANALYSIS DETAILS

|                       |            |               |                |
|-----------------------|------------|---------------|----------------|
| Product:              | 4% CBD oil | Client:       | MariPharm B.V. |
| Batchnumber:          | 2021/05/MP | Contact name: | M. van Haaster |
| Method:               | HPLC       | Address:      | 3029AV/33/NL   |
| Sample delivery date: | 10-05-2021 |               |                |

| CANNABINOID PROFILE                             | RESULT(%)  |
|---|------------|
| $\Delta$ -9-THC (delta-9-tetrahydrocannabinol): | n.d        |
| $\Delta$ -8 THC (delta-8-tetrahydrocannabinol): | n.d        |
| THCA (tetrahydrocannabinolic acid):             | n.d        |
| THCV (tetrahydrocannabivarin):                  | n.d        |
| <u>Total THC</u>                                | n.d        |
| CBD (cannabidiol)                               | 4,20 % m/m |
| CBDA (cannabidiolic acid):                      | n.d        |
| <u>Total CBD</u>                                | 4,20 % m/m |
| CBG (Cannabigerol):                             | n.d        |
| CBGA (Cannabigerolic acid):                     | n.d        |
| CBN (Cannabinol):                               | n.d        |
| CBC (Cannabichromene):                          | n.d        |

\* n.d. = non-detected

### FINAL APPROVAL



Latifa Saddik, Head of Quality Control

Date: 11 May 2021

Testing results are based solely upon the sample submitted to MariPharm Production B.V., in the condition it was received. MariPharm B.V. warrants that all analytical work is conducted professionally in accordance with all applicable standard laboratory practices using validated methods. This report may not be reproduced, except in full, without the written approval of MariPharm B.V.